LivaNova PLC
NASDAQ:LIVNMedical - Devices
+$0.76 today
- Market cap
- $5.21B
- Beta
- 0.88
- P/E (TTM)
- 40.5
- EPS (TTM)
- $1.96
Volume 1.32M
Average 0.79M
LIVN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
LivaNova PLCNASDAQ: LIVN
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development dips below year-ago levels
Q3 FY2026 research & development of $47.7M fell 1.9% year over year, behind the +14.5% change in trailing-twelve-month research & development. Sequentially, it fell 11.2% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.
Context
- Research & development amounted to 13.4% of revenue in FY2025, down 1.2 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -1.9% toward the trailing-twelve-month pace of +14.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 185.8M USD
- Year-over-year change
- +1.8%
- 4-year CAGR
- +0.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 185.8M | +1.8% |
| FY2024 | 2024-12-31 | 182.51M | -5.8% |
| FY2023 | 2023-12-31 | 193.82M | +24.4% |
| FY2022 | 2022-12-31 | 155.81M | -15.1% |
| FY2021 | 2021-12-31 | 183.41M | — |
Research & Development vs competitors
How LIVN compares with its peers on the latest reported figures
- LIVN's LTM Sep 2026 research & development of $202.57M is the 5th highest of the 10 companies compared; the peer median is $99.68M.
- Its year-over-year change of +14.5% is the 2nd highest of 10, against a peer median of +4.9%.
- Research & development amounts to 13.4% of revenue for LIVN, versus a peer median of 10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $2.92B | +4.9% | +2.1% | 7.8% | |
| LTM Jun 2026 | $2.15B | +17.3% | +15.8% | 10.3% | |
| LTM Jun 2026 | $1.09B | +3.3% | +4.5% | 16.7% | |
| LTM Jun 2026 | $378.28M | +14.2% | +9.6% | 6.7% | |
| LTM Sep 2026 | $202.57M | +14.5% | +6.0% | 13.4% | |
| LTM Jun 2026 | $99.68M | -9.7% | +14.5% | 11.1% | |
| LTM Jun 2026 | $59.46M | -4.4% | +0.6% | 4.4% | |
| LTM Mar 2026 | $27.64M | +9.2% | +8.3% | 27.8% | |
| LTM Mar 2026 | $11.7M | +10.5% | +3.8% | 19.8% | |
| LTM Mar 2026 | $6.33M | -47.4% | -11.0% | 4.2% | |
MOBIMobia Medical, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LIVN) | $99.68M | +4.9% | +4.5% | 10.3% | |
Competitors are the stored peer set for LIVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.04B | 1.02B | 1.15B | 1.25B | 1.39B |
| Cost of Revenue | 329.37M | 314.58M | 382.3M | 382.56M | 448.2M |
| Gross Profit | 705.99M | 707.23M | 771.25M | 870.87M | 939.9M |
| Gross Margin | 68.2% | 69.2% | 66.9% | 69.5% | 67.7% |
| Research & Development | 183.41M | 155.81M | 193.82M | 182.51M | 185.8M |
| Selling, General & Admin | 471.9M | 469.24M | 518.13M | 526.27M | 548.8M |
| Operating Expenses | 706.78M | 783.98M | 839.75M | 741.82M | 740.5M |
| Depreciation & Amortization | 67.99M | 57.8M | 60.86M | 51.14M | 42M |
| EBITDA | (6.33M) | 30.9M | 38.48M | 202.52M | (129.5M) |
| EBITDA Margin | -0.6% | 3.0% | 3.3% | 16.2% | -9.3% |
| Operating Income | (784K) | (76.75M) | (68.5M) | 129.05M | 199.4M |
| Operating Margin | -0.1% | -7.5% | -5.9% | 10.3% | 14.4% |
| Interest Income | 435K | 4.7M | 22.01M | 30.08M | 18.98M |
| Interest Expense | 50.15M | 48.25M | 58.85M | 63.07M | 49.29M |
| Other Income / Expenses | (123.84M) | 1.56M | (12.83M) | (40.74M) | (420.2M) |
| Income Before Tax | (124.62M) | (75.2M) | (81.33M) | 88.31M | (220.8M) |
| Pre-Tax Margin | -12.0% | -7.4% | -7.1% | 7.0% | -15.9% |
| Income Tax Expense | 11.2M | 11.05M | (98.88M) | 25.06M | 21.6M |
| Net Income | (135.82M) | (86.25M) | 17.55M | 63.23M | (242.5M) |
| Net Margin | -13.1% | -8.4% | 1.5% | 5.0% | -17.5% |
| EPS (Basic) | (2.68) | (1.61) | 0.33 | 1.17 | (4.45) |
| EPS (Diluted) | (2.68) | (1.61) | 0.32 | 1.16 | (4.45) |
| Weighted Avg Shares | 50.63M | 53.5M | 53.9M | 54.24M | 54.5M |
| Weighted Avg Shares (Diluted) | 50.63M | 53.5M | 54.21M | 54.57M | 54.5M |
LivaNova PLC
NASDAQ:LIVN
Intrinsic Alpha fair value
Locked
Current Price
$94.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.